久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

US EUROPE AFRICA ASIA 中文
Business / Q and A with CEO

Biotech leader continues fast innovation

By Wang Hongyi (China Daily) Updated: 2016-11-11 07:50

Biotech leader continues fast innovation

Severin Schwan, chief executive officer of Roche Group. PROVIDED TO CHINA DAILY

Roche Group looks to grow and change with the country's ever-evolving healthcare industry

Global biotechnology company Roche Group is committed to driving innovation forward in China, which offers a market of 1.3 billion people. With its research and development capabilities in pharmaceuticals and diagnostics, the company has positioned itself to promote personalized healthcare and contribute to China's precision medicine initiatives. Roche's CEO Severin Schwan shared his insights with China Daily reporter Wang Hongyi.

Could you describe Roche's R&D capacity, both globally and in China? What partnerships has Roche already built here?

As a world-leading biotechnology company, we are very much led by science and driven by innovation. We lead the industry with advances in personalized healthcare and our strong oncology portfolio.

R&D receives a greater share of our spending than marketing. On the group level, we spent 9.3 billion Swiss francs ($9.5 billion) on R&D in 2015, which was 19 percent of our turnover. We have consistently been among the top five R&D spenders worldwide, in any industry, since 2009.

Today, we have more than 330 employees in R&D in China. Over the past decades, we've trained a group of outstanding interdisciplinary researchers, leading to highly promising results through collaborations with Chinese companies and academic institutions.

What are your expectations for the new innovation center in Shanghai, which had its groundbreaking ceremony last week?

Last year, we invested 860 million yuan ($126.7 million) in constructing the new laboratory building for the innovation center in Shanghai. The new facility will provide 220 modular workspaces in 14,000 square meters of floor space. We expect it to be completed in 2018.

The focus of our innovation center is very much aligned with the diseases that have a high unmet medical need in China, such as Hepatitis B, which is one of the most prominent diseases in the country.

We hope the new innovation center will spur collaboration between Roche and local research institutions, helping to attract top research talents from both China and overseas.

Our aim is to develop outstanding new drugs for patients in Asia and around the world, and address the currently unmet needs of patients with infectious diseases and those related to immunology and inflammation, thus enhancing our long-term commitment to driving innovation in China.

What is Roche's position on personalized healthcare?

Personalized healthcare is about providing the right treatment for the right patient at the right time. With our combined strength in diagnostics and pharmaceuticals, we are uniquely positioned to further advance personalized healthcare.

In 2006, we made personalized healthcare central to our Roche Group Strategy. This focuses on integrating the knowledge in our pharmaceuticals and diagnostics divisions, and drawing on this knowledge throughout the R&D process, from early research to approval of new diagnostic tests and medicines, as well as their use by patients.

So far, we are the top player in oncology and in vitro diagnostics, drawing from decades of experience in molecular biology.

Today, we are developing two-thirds of our R&D projects with companion diagnostics, which greatly increases efficiency.

In 2015, Roche entered a broad strategic collaboration with Foundation Medicine, a leader in the field of molecular information in oncology, and began to use the latter's innovative genomic sequencing technology to accurately detect the oncogenic mutations in different patients and more effectively help oncologists to find highly-targeted therapies for cancer patients.

In January 2016, Roche announced its cooperation with Flatiron Health in integrating the immense "real world data" and using high-quality healthcare data and advanced analytics to improve both the development of medicines and the quality of treatment decisions.

The cooperation with Foundation Medicine in genomic data and the alliance with Flatiron Health in real world data strengthen Roche's access to innovation and new technologies and drive its commitment to more targeted treatments that, ultimately, make personalized healthcare a reality.

How will Roche promote personalized healthcare in China? What are the difficulties or challenges ahead?

Our diagnostics and pharmaceuticals teams are driving personalized healthcare in China. Roche China Biomarker Team is the first dedicated group in the industry to conduct biomarker studies, focusing on promoting cutting-edge science and technology. The team is mainly engaged in detecting biomarkers and using these techniques in product R&D.

We also provide training on personalized diagnosis and treatment for over 8,000 pathologists and over 4,000 pathology technicians in more than 600 hospitals, laying a solid foundation to improve personalized healthcare in China in the future.

Today, China already has leading companies in genome sequencing and a strong science community. I believe that China has full potential to realize personalized healthcare.

To turn personalized healthcare from a vision to reality is a long journey. The need to improve diagnosis and genetic testing, and the current lack of good quality patient data are problems that should be addressed. We are committed to supporting the Chinese government in overcoming these challenges.

How do you view China's rapid economic growth and its recent slowdown? Will this affect Roche's development in this market?

As one of the first multinational companies to enter China 20 years ago, we've witnessed the country's fastgrowth economy and its booming healthcare market.

The recent slowdown is a sign of China's transition to a new normal, toward building a more sustainable economy based on the consumption and service industries. A high value-added sector such as healthcare can be a new pillar of economic growth in this model.

With the slowing of economic growth, cost containment measures on off-patent drugs and the delayed launch of new drugs, 2015 is the first year since 2005 that the Chinese pharmaceutical industry is facing single-digit growth.

Despite short-term challenges, I am optimistic about the market's growth potential. With an aging population, China's demand for high-end healthcare and treatment for chronic diseases has increased rapidly over the past few years, in response to elderly patients' healthcare needs.

As part of its healthcare reform, the Chinese government is increasing overall spending on healthcare to broaden reimbursement coverage, especially for critical illnesses, and accelerating new drug approvals.

In the short term, we will benefit from expanded healthcare and reimbursement coverage for critical illnesses. In the mid-to-long term, we anticipate our business to grow more quickly, benefiting from the launch of new drugs.

How would you evaluate China's performance globally? Will Roche increase its investment in China?

China remains one of our most important markets globally. We have invested considerably to build a full value chain in China from R&D and manufacturing through to commercialization.

In diagnostics, China is already the second-largest country for us. In pharmaceuticals, China is our third-largest national market.

We recognize that China's pharmaceutical market environment is facing a challenging phase in the short term. However with our strong pipeline and dedicated people, we are confident about our long-term growth prospects by bringing more innovative products to China to benefit more patients.

What do you think of the opportunities and challenges facing your company amid recent healthcare reform? How does Roche fit into the national strategy of "building a healthy China"?

Since 2009, China's healthcare reforms have had far-reaching implications for the industry's long-term development.

The positive moves toward a more transparent and effective review process and capability building at the China Food and Drug Administration are promising for Chinese patients, as well as for innovation-driven companies like us.

We are very encouraged about the update to the National Reimbursed Drug List and hope that national reimbursement coverage can be broadened to critical illnesses.

There remain affordability challenges in China, but we are optimistic that with joint efforts from multiple stakeholders, including the Chinese government and companies like us, more and more patients will have the opportunity to access high-quality treatment.

Roche has been actively working together with different stakeholders, such as local governments, charity foundations, NGOs and insurance companies. We are looking to address unmet patient needs through reimbursement listings on the provincial and city level, patient access programs and private insurance offerings.

How do you motivate international teams?

I think people should be given more space and chances to increase their creativity.

In an organization, people should not be told what to do or what not to do. They should be given opportunities to make full use of their potential.

During this process, a leader should work to encourage them to achieve greater innovation rather than allocate them more tasks.

Hot Topics

Editor's Picks
...
久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

    乱一区二区av| 91欧美一区二区| 久久久91精品国产一区二区精品| 精品一区二区三区的国产在线播放| 精品国产1区二区| 国产精品996| 亚洲精品ww久久久久久p站| 欧美视频一区二区在线观看| 日本vs亚洲vs韩国一区三区 | 国模大尺度一区二区三区| 久久久久久一级片| 91视视频在线直接观看在线看网页在线看| 一区二区三区在线视频免费观看| 欧美日韩一区二区在线观看 | 久久久精品影视| 色综合天天综合| 日韩国产欧美视频| 国产欧美日韩一区二区三区在线观看| 91视频在线看| 免费人成黄页网站在线一区二区| 中文字幕欧美区| 欧美性感一类影片在线播放| 精品中文字幕一区二区小辣椒| 国产精品第四页| 欧美精品精品一区| 国产成人亚洲精品青草天美| 亚洲精选视频在线| 日韩欧美国产一二三区| 99精品欧美一区二区三区小说| 午夜电影网一区| 欧美韩国日本综合| 欧美久久久久久久久| 国产经典欧美精品| 亚洲成人综合网站| 久久久国产精品午夜一区ai换脸| 色综合色综合色综合色综合色综合| 蜜桃传媒麻豆第一区在线观看| 亚洲欧洲日产国产综合网| 日韩三级电影网址| 色婷婷国产精品久久包臀 | 久久电影国产免费久久电影| 亚洲日本韩国一区| 欧美va日韩va| 欧美色图片你懂的| 成人av综合一区| 久久精品av麻豆的观看方式| 一区二区三区电影在线播| 久久久久99精品一区| 欧美日韩精品一二三区| 菠萝蜜视频在线观看一区| 免费高清不卡av| 一级女性全黄久久生活片免费| 久久精品一区二区三区四区| 欧美精品一级二级| 色综合久久天天| 国产成人av影院| 日本vs亚洲vs韩国一区三区| 亚洲女爱视频在线| 国产亚洲福利社区一区| 欧美一区二区成人| 欧美一a一片一级一片| 成人福利电影精品一区二区在线观看| 美女脱光内衣内裤视频久久影院| 一区二区免费看| 国产精品久久久久9999吃药| 久久久久久9999| 91精品国产美女浴室洗澡无遮挡| 91国偷自产一区二区三区观看| 丁香天五香天堂综合| 精品一区二区日韩| 日本va欧美va精品发布| 亚洲一区二区三区不卡国产欧美| 国产精品久久久久久久久果冻传媒| 精品欧美乱码久久久久久 | 亚洲精品国产精品乱码不99| 中文字幕巨乱亚洲| 久久夜色精品国产噜噜av| 欧美一区欧美二区| 在线播放国产精品二区一二区四区| 色综合一个色综合| 91尤物视频在线观看| 成人免费av资源| 国产成人精品午夜视频免费| 紧缚捆绑精品一区二区| 奇米精品一区二区三区在线观看| 午夜精品在线视频一区| 亚洲国产成人精品视频| 亚洲激情av在线| 一区二区三区高清| 一区二区三区四区五区视频在线观看 | 精品国产露脸精彩对白| 日韩精品专区在线影院重磅| 日韩一区二区高清| 日韩欧美一级在线播放| 日韩三级视频在线观看| 欧美一区二区三区免费大片| 日韩一级视频免费观看在线| 91精品国产综合久久精品| 在线播放欧美女士性生活| 欧美高清hd18日本| 欧美一级xxx| 欧美tickle裸体挠脚心vk| 精品国产乱码久久久久久蜜臀| 欧美电视剧在线观看完整版| 欧美电影免费观看完整版| 精品欧美乱码久久久久久1区2区| 亚洲精品在线三区| 国产丝袜在线精品| 中文字幕第一页久久| 国产精品理伦片| 亚洲欧洲制服丝袜| 亚洲一二三区不卡| 日日嗨av一区二区三区四区| 美女网站在线免费欧美精品| 国模娜娜一区二区三区| 懂色av噜噜一区二区三区av| fc2成人免费人成在线观看播放 | 蜜臀av性久久久久av蜜臀妖精| 久久精品免费观看| 国产精品亚洲综合一区在线观看| 成人激情校园春色| 日本韩国一区二区| 欧美三日本三级三级在线播放| 欧美电影在哪看比较好| 欧美大片在线观看一区| 国产午夜一区二区三区| 最新国产精品久久精品| 亚洲精品亚洲人成人网在线播放| 亚洲成人动漫在线观看| 麻豆视频一区二区| 国产suv精品一区二区6| 色综合欧美在线| 欧美电影一区二区| 337p粉嫩大胆色噜噜噜噜亚洲| 亚洲国产精品v| 亚洲制服丝袜一区| 美女精品一区二区| 成人ar影院免费观看视频| 欧美亚洲综合网| 精品奇米国产一区二区三区| 国产精品美女久久久久aⅴ | 久久成人羞羞网站| 成人av资源在线| 欧美老肥妇做.爰bbww视频| 久久亚洲欧美国产精品乐播| 自拍偷拍亚洲欧美日韩| 日本在线不卡视频一二三区| 国产精品一区在线观看乱码| 色欧美88888久久久久久影院| 日韩一区二区三区视频在线| 国产精品欧美经典| 天天综合色天天综合色h| 国产精品一级片| 欧美日韩一区二区在线观看视频| 26uuu久久天堂性欧美| 亚洲精品国产视频| 精品亚洲欧美一区| 91久久线看在观草草青青| 日韩你懂的在线观看| 亚洲图片另类小说| 久久精品国产77777蜜臀| 色综合一区二区| 精品日韩av一区二区| 一区二区三区四区国产精品| 久久精品国产秦先生| 91亚洲国产成人精品一区二三| 欧美成人激情免费网| 一区二区三区中文免费| 欧美日韩亚洲丝袜制服| 欧美精品一区二区在线播放| 一区二区三区欧美在线观看| 国产自产2019最新不卡| 欧美日韩专区在线| 中国av一区二区三区| 日本视频一区二区| 色噜噜狠狠色综合中国| 久久亚洲精精品中文字幕早川悠里| 亚洲综合在线电影| 成人自拍视频在线观看| 日韩一级完整毛片| 亚洲与欧洲av电影| 不卡的电影网站| 久久综合视频网| 日韩影院精彩在线| 色婷婷av一区二区三区之一色屋| 国产亚洲人成网站| 青草av.久久免费一区| 欧洲av一区二区嗯嗯嗯啊| 亚洲国产高清不卡| 国精产品一区一区三区mba视频 | 欧美日韩久久久一区| 国产精品久久久久久久久久久免费看 | 青椒成人免费视频| 欧美午夜一区二区三区免费大片| 国产精品久久久久影院老司| 国产在线一区观看| 日韩视频不卡中文| 天天影视色香欲综合网老头| 91久久久免费一区二区| 国产精品久久久久三级|